BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seo J, Smith BD, Estey E, Voyard E, O' Donoghue B, Bridges JFP. Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development. Curr Med Res Opin 2018;34:2031-9. [PMID: 29565196 DOI: 10.1080/03007995.2018.1456414] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Cole A, Richardson DR, Adapa K, Khasawneh A, Crossnohere NL, Bridges JF, Mazur L. Development of a patient-centered preference tool for patients with hematologic malignancies: protocol for a mixed methods study (Preprint). JMIR Research Protocols. [DOI: 10.2196/39586] [Reference Citation Analysis]
2 Assouline S, Wiesinger A, Spooner C, Jovanović J, Schlueter M. Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103711] [Reference Citation Analysis]
3 Collacott H, Soekhai V, Thomas C, Brooks A, Brookes E, Lo R, Mulnick S, Heidenreich S. A Systematic Review of Discrete Choice Experiments in Oncology Treatments. Patient 2021. [PMID: 33950476 DOI: 10.1007/s40271-021-00520-4] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
4 Richardson DR, Oakes AH, Crossnohere NL, Rathsmill G, Reinhart C, O'Donoghue B, Bridges JFP. Prioritizing the worries of AML patients: Quantifying patient experience using best-worst scaling. Psychooncology 2021;30:1104-11. [PMID: 33544421 DOI: 10.1002/pon.5652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Webb EJD, Meads D, Lynch Y, Judge S, Randall N, Goldbart J, Meredith S, Moulam L, Hess S, Murray J. Attribute Selection for a Discrete Choice Experiment Incorporating a Best-Worst Scaling Survey. Value Health 2021;24:575-84. [PMID: 33840436 DOI: 10.1016/j.jval.2020.10.025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Crawford R, Sully K, Conroy R, Johnson C, Doward L, Bell T, Welch V, Peloquin F, Gater A. Patient-Centered Insights on Treatment Decision Making and Living with Acute Myeloid Leukemia and Other Hematologic Cancers. Patient 2020;13:83-102. [PMID: 31456136 DOI: 10.1007/s40271-019-00384-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
7 Estey EH. Acute myeloid leukemia: 2021 update on risk-stratification and management. Am J Hematol 2020;95:1368-98. [PMID: 32833263 DOI: 10.1002/ajh.25975] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
8 Shields GE, Brown L, Wells A, Capobianco L, Vass C. Utilising Patient and Public Involvement in Stated Preference Research in Health: Learning from the Existing Literature and a Case Study. Patient 2021;14:399-412. [PMID: 32748242 DOI: 10.1007/s40271-020-00439-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Richardson DR, Crossnohere NL, Seo J, Estey E, O'Donoghue B, Smith BD, Bridges JFP. Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful Benefits. Cancer Epidemiol Biomarkers Prev 2020;29:942-8. [PMID: 32132149 DOI: 10.1158/1055-9965.EPI-19-1277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
10 Booth A, Bell T, Halhol S, Pan S, Welch V, Merinopoulou E, Lambrelli D, Cox A. Using Social Media to Uncover Treatment Experiences and Decisions in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Who Are Ineligible for Intensive Chemotherapy: Patient-Centric Qualitative Data Analysis. J Med Internet Res 2019;21:e14285. [PMID: 31755871 DOI: 10.2196/14285] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
11 Crossnohere NL, Richardson DR, Reinhart C, O'Donoghue B, Love SM, Smith BD, Bridges JFP. Side effects from acute myeloid leukemia treatment: results from a national survey. Curr Med Res Opin 2019;35:1965-70. [PMID: 31188058 DOI: 10.1080/03007995.2019.1631149] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
12 Jackson Y, Janssen E, Fischer R, Beaverson K, Loftus J, Betteridge K, Rhoten S, Flood E, Lundie M. The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management. Expert Rev Pharmacoecon Outcomes Res 2019;19:383-96. [PMID: 31070048 DOI: 10.1080/14737167.2019.1612242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
13 LeBlanc TW, Baile WF, Eggly S, Bylund CL, Kurtin S, Khurana M, Najdi R, Blaedel J, Wolf JL, Fonseca R. Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies. Patient Educ Couns 2019;102:1602-12. [PMID: 31076236 DOI: 10.1016/j.pec.2019.04.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
14 Bridges JFP, Tsai J, Janssen E, Crossnohere NL, Fischer R, Peay H. How Do Members of the Duchenne and Becker Muscular Dystrophy Community Perceive a Discrete-Choice Experiment Incorporating Uncertain Treatment Benefit? An Application of Research as an Event. Patient 2019;12:247-57. [DOI: 10.1007/s40271-018-0330-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]